Glucagon-like peptide 1 and cardiac cell survival;Péptido similar al glucagón tipo 1 y supervivencia de la célula cardiaca

Endocrinologia y Nutricion

Volumn 59, Issue 9, 2012, Pages 561-569

  Ravassa, Susana ^a   Zudaire, Amaia ^a   Díez, Javier ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Apoptosis; Glucagon like peptide 1; Heart failure; Myocardial infarction; Necrosis

Indexed keywords

GLUCAGON LIKE PEPTIDE 1;

CELL SURVIVAL; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; HEART VENTRICLE REMODELING; HUMAN; SHORT SURVEY;

ANIMALS; CARDIOTONIC AGENTS; CELL SURVIVAL; CELLS, CULTURED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG EVALUATION, PRECLINICAL; ENTEROENDOCRINE CELLS; ENZYME ACTIVATION; GLUCAGON-LIKE PEPTIDE 1; HEART FAILURE; HEART FUNCTION TESTS; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCYTES, CARDIAC; PEPTIDE FRAGMENTS; PROTEIN KINASES; SIGNAL TRANSDUCTION;

EID: 84868639683     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2012.07.007     Document Type: Short Survey

References (73)

1. Whelan R.S., Kaplinskiy V., Kitsis R.N. Cell death in the pathogenesis of heart disease: mechanisms and significance. Annu Rev Physiol 2010, 72:19-44.
2. Rosano G.M., Fini M., Caminiti G., Barbaro G. Cardiac metabolism in myocardial ischemia. Curr Pharm Des 2008, 14:2551-2562.
3. Braunwald E., Kloner R.A. Myocardial reperfusion: a double-edged sword?. J Clin Invest 1985, 76:1713-1719.
4. Ibanez B., Fuster V., Jiménez-Borreguero J., Badimon J.J. Lethal myocardial reperfusion injury: a necessary evil?. Int J Cardiol 2011, 151:3-11.
5. Gottlieb R.A., Burleson K.O., Kloner R.A., Babior B.M., Engler R.L. Reperfusion injury induces apoptosis in rabbit cardiomyocytes. J Clin Invest 1994, 94:1621-1628.
6. Hausenloy D.J., Yellon D.M. New directions for protecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury Salvage Kinase (RISK)-pathway. Cardiovasc Res 2004, 61:448-460.
7. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-1135.
8. Hausenloy D.J., Yellon D.M. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007, 12:217-234.
9. Elrick H., Stimmler L., Hlad C.J J.R., Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964, 24:1076-1082.
10. McIntyre N., Holdsworth C.D., Turner D.S. Intestinal factors in the control of insulin secretion. J Clin Endocrinol Metab 1965, 25:1317-1324.
11. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
12. Deacon C.F., Johnsen A.H., Holst J.J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 1995, 80:952-957.
13. Knudsen L.B., Pridal L. Glucagon-like peptide-1-(9-36) amide is a major metabolite of glucagon-like peptide-1-(7-36) amide after in vivo administration to dogs, and it acts as an antagonist on the pancreatic receptor. Eur J Pharmacol 1996, 318:429-435.
14. Nauck M.A. Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011, 124:S3-S18.
15. Marzioni M., Alpini G., Saccomanno S., Candelaresi C., Venter J., Rychlicki C., et al. Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut 2009, 58:990-997.
16. Harkavyi A., Whitton P.S. Glucagon-like peptide 1 receptor stimulation as a means of neuroprotection. Br J Pharmacol 2010, 159:495-501.
17. Lavine J.A., Attie A.D. Gastrointestinal hormones and the regulation of β-cell mass. Ann N Y Acad Sci 2010, 1212:41-58.
18. Wajchenberg B.L. Clinical approaches to preserve beta-cell function in diabetes. Adv Exp Med Biol 2010, 654:515-535.
19. Li L., El-Kholy W., Rhodes C.J., Brubaker P.L. Glucagon-like peptide-1 protects beta cells from cytokine-induced apoptosis and necrosis: role of protein kinase B. Diabetologia 2005, 48:1339-1349.
20. Tomas E., Stanojevic V., Habener J.F. GLP-1-derived nonapeptide GLP-1(28-36) amide targets to mitochondria and suppresses glucose production and oxidative stress in isolated mouse hepatocytes. Regul Pept 2011, 167:177-184.
21. Ussher J.R., Drucker D.J. Cardiovascular biology of the incretin system. Endocr Rev 2012, 33:187-215.
22. Yoon J.S., Lee H.W. Understanding the cardiovascular effects of incretin. Diabetes Metab J 2011, 35:437-443.
23. Anagnostis P., Athyros V.G., Adamidou F., Panagiotou A., Kita M., Karagiannis A., et al. Glucagon-like peptide-1-based therapies and cardiovascular disease: looking beyond glycaemic control. Diabetes Obes Metab 2011, 13:302-312.
24. Plutzky J. The incretin axis in cardiovascular disease. Circulation 2011, 124:2285-2289.
25. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
26. Bullock B.P., Heller R.S., Habener J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996, 137:2968-2978.
27. Wei Y., Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995, 358:219-224.
28. Gros R., You X., Baggio L.L., Kabir M.G., Sadi A.M., Mungrue I.N., et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003, 144:2242-2252.
29. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
30. Matsui T., Tao J., del Monte F., Lee K.H., Li L., Picard M., et al. Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo. Circulation 2001, 104:330-335.
31. Davidson M.H. Cardiovascular effects of glucagonlike peptide-1 agonists. Am J Cardiol 2011, 108:33B-41B.
32. Ku H.C., Chen W.P., Su M.J. GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn Schmiedebergs Arch Pharmacol 2010, 382:463-474.
33. Sauvé M., Ban K., Momen M.A., Zhou Y.Q., Henkelman R.M., Husain M., et al. Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 2010, 59:1063-1073.
34. Ku H.C., Chen W.P., Su M.J. DPP4 deficiency preserves cardiac function via GLP-1 signaling in rats subjected to myocardial ischemia/reperfusion. Naunyn Schmiedebergs Arch Pharmacol 2011, 384:197-207.
35. Hlebowicz J., Lindstedt S., Bjorgell O., Dencker M. The effect of endogenously released glucose, insulin, glucagon-like peptide 1, ghrelin on cardiac output, heart rate, stroke volume, and blood pressure. Cardiovasc Ultrasound 2011, 9:43.
36. Nathanson D., Zethelius B., Berne C., Lind L., Andrén B., Ingelsson E., et al. Plasma levels of glucagon like peptide-1 associate with diastolic function in elderly men. Diabet Med 2011, 28:301-305.
37. Narula J., Haider N., Virmani R., DiSalvo T.G., Kolodgie F.D., Hajjar R.J., et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 1996, 335:1182-1189.
38. Nakayama H., Chen X., Baines C.P., Klevitsky R., Zhang X., Zhang H., et al. Ca2+- and mitochondrial-dependent cardiomyocyte necrosis as a primary mediator of heart failure. J Clin Invest 2007, 117:2431-2444.
39. Guerra S., Leri A., Wang X., Finato N., di Loreto C., Beltrami C.A., et al. Myocyte death in the failing human heart is gender dependent. Circ Res 1999, 85:856-866.
40. Ban K., Kim K.H., Cho C.K., Sauvé M., Diamandis E.P., Backx P.H., et al. Glucagon-like peptide (GLP)-1(9-36) amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010, 151:1520-1531.
41. Xie Y., Wang S.X., Sha W.W., Zhou X., Wang W.L., Han L.P., et al. Effects and mechanism of glucagon-like peptide-1 on injury of rats cardiomyocytes induced by hypoxia-reoxygenation. Chin Med J (Engl) 2008, 121:2134-2138.
42. Noyan-Ashraf M.H., Momen M.A., Ban K., Sadi A.M., Zhou Y.Q., Riazi A.M., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983.
43. Ravassa S., Zudaire A., Carr R.D., Díez J. Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes. Am J Physiol Heart Circ Physiol 2011, 300:H1361-H1372.
44. Matsubara M., Kanemoto S., Leshnower B.G., Albone E.F., Hinmon R., Plappert T., et al. Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury. J Surg Res 2011, 165:38-45.
45. Timmers L., Henriques J.P., de Kleijn D.P., Devries J.H., Kemperman H., Steendijk P., et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009, 53:501-510.
46. Bao W., Aravindhan K., Alsaid H., Chendrimada T., Szapacs M., Citerone D.R., et al. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One 2011, 6:e23570.
47. Brown S.B., Libonati J.R., Selak M.A., Shannon R.P., Simmons R.A. Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heart. Cardiovasc Drugs Ther 2010, 24:197-205.
48. Sonne D.P., Engstrøm T., Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008, 146:243-249.
49. Iwasa M., Kobayashi H., Yasuda S., Kawamura I., Sumi S., Yamada Y., et al. Antidiabetic drug voglibose is protective against ischemia-reperfusion injury through glucagon-like peptide 1 receptors and the phosphoinositide 3-kinase-Akt-endothelial nitric oxide synthase pathway in rabbits. J Cardiovasc Pharmacol 2010, 55:625-634.
50. Iwasa M., Yamada Y., Kobayashi H., Yasuda S., Kawamura I., Sumi S., et al. Both stimulation of GLP-1 receptors and inhibition of glycogenolysis additively contribute to a protective effect of oral miglitol against ischaemia-reperfusion injury in rabbits. Br J Pharmacol 2011, 164:119-131.
51. Nikolaidis L.A., Doverspike A., Hentosz T., Zourelias L., Shen Y.T., Elahi D., et al. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J Pharmacol Exp Ther 2005, 312:303-308.
52. Bose A.K., Mocanu M.M., Carr R.D., Yellon D.M. Myocardial ischaemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 2007, 21:253-256.
53. Ye Y., Keyes K.T., Zhang C., Perez-Polo J.R., Lin Y., Birnbaum Y. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010, 298:H1454-H1465.
54. Huisamen B., Genade S., Lochner A. Signalling pathways activated by glucagon-like peptide-1 (7-36) amide in the rat heart and their role in protection against ischaemia. Cardiovasc J Afr 2008, 19:77-83.
55. Huisamen B., Genis A., Marais E., Lochner A. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 2011, 25:13-20.
56. Dokken B.B., La Bonte L.R., Davis-Gorman G., Teachey M.K., Seaver N., McDonagh P.F. Glucagon-like peptide-1 (GLP-1), immediately prior to reperfusion, decreases neutrophil activation and reduces myocardial infarct size in rodents. Horm Metab Res 2011, 43:300-305.
57. Dokken B.B., Hilwig W.R., Teachey M.K., Panchal R.A., Hubner K., Allen D., et al. Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction. Resuscitation 2010, 81:755-760.
58. Zhao T., Parikh P., Bhashyam S., Bolukoglu H., Poornima I., Shen Y.T., et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006, 317:1106-1113.
59. Kristensen J., Mortensen U.M., Schmidt M., Nielsen P.H., Nielsen T.T., Maeng M. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc Disord 2009, 9:31.
60. Kavianipour M., Ehlers M.R., Malmberg K., Ronquist G., Ryden L., Wikström G., et al. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides 2003, 24:569-578.
61. White F.C., Bloor C.M. Coronary collateral circulation in the pig: correlation of collateral flow with coronary bed size. Basic Res Cardiol 1981, 76:189-196.
62. Yin M., Silljé H.H., Meissner M., van Gilst W.H., de Boer R.A. Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure. Cardiovasc Diabetol 2011, 10:85.
63. Zaruba M.M., Zhu W., Soonpaa M.H., Reuter S., Franz W.M., Field L.J. Granulocyte colony-stimulating factor treatment plus dipeptidylpeptidase-IV inhibition augments myocardial regeneration in mice expressing cyclin D2 in adult cardiomyocytes. Eur Heart J 2012, 33:129-137.
64. Poornima I., Brown S.B., Bhashyam S., Parikh P., Bolukoglu H., Shannon R.P. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ Heart Fail 2008, 1:153-160.
65. Liu Q., Anderson C., Broyde A., Polizzi C., Fernandez R., Baron A., et al. Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure. Cardiovasc Diabetol 2010, 9:76.
66. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004, 110:955-961.
67. Nikolaidis L.A., Elahi D., Shen Y.T., Shannon R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol 2005, 289:H2401-H2408.
68. Vyas A.K., Yang K.C., Woo D., Tzekov A., Kovacs A., Jay P.Y., et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS One 2011, 6:e17178.
69. Mells J.E., Fu P.P., Sharma S., Olson D., Cheng L., Handy J.A., et al. Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet. Am J Physiol Gastrointest Liver Physiol 2012, 302:G225-G235.
70. Yu M., Moreno C., Hoagland K.M., Dahly A., Ditter K., Mistry M., et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003, 21:1125-1135.
71. Chaykovska L., von Websky K., Rahnenführer J., Alter M., Heiden S., Fuchs H., et al. Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy. PLoS One 2011, 6:e27861.
72. Ovalle F. Cardiovascular implications of antihyperglycemic therapies for type 2 diabetes. Clin Ther 2011, 33:393-407.
73. Giorgino F., Leonardini A., Natalicchio A., Laviola L. Multifactorial intervention in Type 2 diabetes: the promise of incretin-based therapies. J Endocrinol Invest 2011, 34:69-77.